Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Targeting Myosteatosis Though Physical Exercise to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
60 participants
Sep 1, 2025
INTERVENTIONAL
Conditions
Summary
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.
Eligibility
Inclusion Criteria3
- confirmed MASLD at abdominal imaging
- confirmed excessive muscle lipid content at imaging
- stable weight
Exclusion Criteria3
- severe comorbidities including active malignancies, neuromuscular degenerative diseases
- contraindications to physical activity
- excessive alcohol consumption
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
High-intensity interval training
Moderate intensity exercise training
Low intensity exercise training
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06506513